The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Lady Gaga is set to take on Chappell Roan for Number 1 this week – Abracadabra (2) is less than 1,400 chart units away from Pink Pony Club (1), which became the first UK chart-topper for pop ...

The Official Chart is turned into the Pink Pony Club today, as Chappell Roan finally secures her first UK Number 1 single. Pink Pony Club go-go dances to the top of the Official Singles Chart ...

If a language can be used to build web scrapers, it definitely needs to provide a graceful data visualization library. --- by dongdong. In the Golang ecosystem, there are not many choices for data ...

Otulfi® is an ustekinumab biosimilar for the reference product Stelara® (ustekinumab ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg ...

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg/mL ...

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...

One Piece chapter 1141 spoilers were expected to focus on Figarland Shamrock and the Holy Knights as they began their plan to abduct Elbaphian children from the Walrus School. Unofficially leaked ...

"Stelara has long been a cornerstone treatment for chronic inflammatory conditions, but with an annual cost up to $125,000 per patient, it's a financial burden on members and payers alike," said ...